Life Science Investing Sonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special Meeting
Life Science Investing Evaluation of SON-1010 Using a Patient-Derived Tumoroid Platform to Support an Ongoing Phase 1 Study in Patients with Sarcoma